According to Zacks, “Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company’s initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. “
Other research analysts have also issued research reports about the stock. BidaskClub lowered shares of Cerus from a “buy” rating to a “hold” rating in a research report on Friday, August 9th. ValuEngine raised shares of Cerus from a “hold” rating to a “buy” rating in a research report on Tuesday, July 23rd.
Shares of CERS opened at $5.21 on Wednesday. The company has a 50-day simple moving average of $5.45 and a 200-day simple moving average of $5.74. The firm has a market capitalization of $732.47 million, a P/E ratio of -11.84 and a beta of 1.60. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.33 and a current ratio of 2.67. Cerus has a 52 week low of $4.49 and a 52 week high of $7.81.
Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.01). The company had revenue of $18.20 million for the quarter, compared to analyst estimates of $17.55 million. Cerus had a negative net margin of 98.69% and a negative return on equity of 85.73%. The firm’s quarterly revenue was up 18.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.10) EPS. As a group, equities analysts forecast that Cerus will post -0.49 earnings per share for the current year.
In related news, insider Richard J. Benjamin sold 16,444 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $5.01, for a total value of $82,384.44. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider William Mariner Greenman bought 10,000 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was acquired at an average cost of $4.60 per share, for a total transaction of $46,000.00. Following the purchase, the insider now owns 638,485 shares of the company’s stock, valued at $2,937,031. The disclosure for this purchase can be found here. 7.26% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its holdings in Cerus by 6.3% during the fourth quarter. Bank of New York Mellon Corp now owns 570,454 shares of the biotechnology company’s stock worth $2,892,000 after acquiring an additional 33,898 shares during the period. Geode Capital Management LLC grew its holdings in Cerus by 5.5% during the fourth quarter. Geode Capital Management LLC now owns 1,516,092 shares of the biotechnology company’s stock worth $7,685,000 after acquiring an additional 78,401 shares during the period. Principal Financial Group Inc. grew its holdings in Cerus by 81.0% during the fourth quarter. Principal Financial Group Inc. now owns 81,368 shares of the biotechnology company’s stock worth $413,000 after acquiring an additional 36,410 shares during the period. Bank of America Corp DE grew its holdings in Cerus by 12.9% during the fourth quarter. Bank of America Corp DE now owns 535,458 shares of the biotechnology company’s stock worth $2,714,000 after acquiring an additional 61,275 shares during the period. Finally, Legal & General Group Plc grew its holdings in Cerus by 19.3% during the fourth quarter. Legal & General Group Plc now owns 26,148 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 4,222 shares during the period. 71.78% of the stock is currently owned by institutional investors and hedge funds.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
See Also: Why do companies pay special dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.